Author

Giuseppe Deluliis

Yale University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Systems Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Organism:human· 1

Frequent Co-Authors

Farida AhangariiD· 2 shared Naftali KaminskiiD· 2 shared Thomas BärnthaleriD· 2 shared A. JustetiD· 1 shared Anna BackmarkiD· 1 shared Benjamin P. Readhead· 1 shared Björn Magnusson· 1 shared Carlos CosmeiD· 1 shared

Activity by Year

2022-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSystems Biology

Farida AhangariORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Sobetirome, a thyroid hormone receptor beta agonist, is a potential therapeutic agent for pulmonary fibrosis

Thomas Bärnthaler, shuiz Ding, Taylor Sterling Adams, Kady-Ann Rose, Reina Rangel, Johad Khoury, Melika Salimi, Sabina Anderson, Liqin Lin, Karen Y. Velasco-Alzate, Fernando Poli de Frias, Giuseppe Deluliis, Fadi Nicola, Carlos Cosme, A. Justet, , Farida Ahangari

This study shows that sobetirome, a thyroid hormone receptor beta agonist, reduces pulmonary fibrosis in mice and human tissue by restoring mitochondrial function and modulating apoptosis.

bioRxiv · Sep 3, 2026 · PreprintSystems Biology

Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in In Vitro, In Vivo and Ex Vivo Models of Pulmonary Fibrosis

Farida Ahangari, Christine Becker, Daniel G. Foster, Maurizio Chioccioli, Meghan Nelson, K.M. Beke, Xing Wang, Benjamin P. Readhead, Carly Meador, Kelly A. Correll, Loukia N. Lili, Helen M. Roybal, Kadi-Ann Rose, Shuizi Ding, Thomas Bärnthaler, , Gregory Paul Downey

This study identifies saracatinib as a potential anti-fibrotic drug effective in multiple models of pulmonary fibrosis, showing equal or superior efficacy compared to existing treatments.

bioRxiv · Jan 4, 2022 · PreprintSystems Biology